<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100708</url>
  </required_header>
  <id_info>
    <org_study_id>PIPAC_01</org_study_id>
    <nct_id>NCT03100708</nct_id>
  </id_info>
  <brief_title>Register Study of Patients With Peritoneal Carcinomatosis Treated With PIPAC (Pressurized Intra-peritoneal Aerosol-Chemotherapy)</brief_title>
  <acronym>PIPAC_01</acronym>
  <official_title>Evaluation of Molecular and Pathophysiological Mechanisms of Peritoneal Carcinomatosis and Monitoring of the Efficiency of PIPAC (Pressurized Intra-peritoneal Aerosol-Chemotherapy) as a Local Chemotherapeutical Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will follow up patients with peritoneal carcinomatosis from colorectal, ovarian,
      gastric, pancreatic cancers and primary peritoneal tumors and undergoing a diagnostic
      laparoscopy / laparotomy, a PIPAC as single dose or repeated every 6 weeks. The Overall
      Response Rate (ORR), the Overall Survival (OS) and the Quality of Life will be assessed
      before every PIPAC. Biopsies of the peritoneal carcinomatosis and blood (plasma and serum)
      are collected with every PIPAC intervention to follow up and to document the individual
      success or progress of the patients. The advice of the tumor board is mandatory to confirm
      the indication for local chemotherapy (PIPAC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (years)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Peritoneal Carcinomatosis Index (PCI) before and after repeated PIPAC treatments</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (CT RESIST criteria)</measure>
    <time_frame>5 years</time_frame>
    <description>Complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of lfe questionnaire (EORTC QLQ-C15-PAL)</measure>
    <time_frame>5 years</time_frame>
    <description>Groenvold M et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. European Journal of Cancer 2006; 42(1): 55-64</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Patient with peritoneal carcinomatosis</arm_group_label>
    <description>Patient with peritoneal carcinomatosis and the Indication for local therapy. The Clinics tumor-board advice is needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PIPAC</intervention_name>
    <description>Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.
Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.
The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system.</description>
    <arm_group_label>Patient with peritoneal carcinomatosis</arm_group_label>
    <other_name>Pressurized Intra-peritoneal Aerosol-Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffer from peritoneal carcinomatosis.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with clinical and pathological confirmed peritoneal carcinomatosis from
             gastric, colorectal, pancreatic, ovarian cancers or primary peritoneal tumors

          -  Age &gt; 18 years

          -  signed informed consent

        Exclusion Criteria:

          -  Patient can not understand meaning and purpose of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ines Gockel, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ines Gockel, Prof. Dr.</last_name>
    <phone>+49 341 97 17200</phone>
    <email>ines.gockel@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Boris Jansen-Winkeln, Dr.</last_name>
    <phone>+49 341 97 17200</phone>
    <email>boris.jansen-winkeln@medizin.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig - AöR</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Dr. Boris Jansen-Winkeln</investigator_full_name>
    <investigator_title>Dr. B. Jansen-Winkeln and Prof. Dr. I. Gockel</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

